Prot# NU UIC06CC12: An Open Label Phase II Study of Aprepitant for Multi-Day Moderately-High to Highly Emetogenic Chemotherapy Regimens

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/1/07 → 8/31/08

Funding

  • University of Illinois at Chicago (NU UIC06CC12 // NU UIC06CC12)
  • Merck & Co., Inc. (NU UIC06CC12 // NU UIC06CC12)